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Purpose: Highly sensitized patients with a high level of panel reactive antibody (PRA) experience more episodes of anti-
body-mediated rejection (AMR) and poorer graft survival than non-sensitized patients. Rituximab is a well-known mono-
clonal anti-CD20 antibody that causes the depletion of B lymphocytes. The aim of this study was to compare a rituximab-ad-
ministered and a non-administered group of highly sensitized recipients. Methods: Forty-three kidney recipients with a PRA 
level of ≥50% were included. Sixteen (group R) received one dose of rituximab at 2 days prior to transplantation and 27 pa-
tients (group NR) did not. Results: Patients’ demographics, such as age, sex, dialysis duration, and type of immuno-
suppressive agent were not different in the two groups. No side effects due to rituximab administration were observed in 
group R. Class I PRA of group R (75.6 ± 37.7%) was higher than that of group NR (45.7 ± 35.8%, P = 0.013). More acute re-
jection episodes occurred within 1 year after transplantation in group NR but the difference between the groups was not sig-
nificant (18.8% in group R vs. 29.6% in group NR, P = 0.631). However, two AMR episodes occurred only in group NR. Renal 
functions were not different in the two groups. In group R, CD19 and CD20 rapidly decreased 2 days after rituximab 
infusion. Furthermore, the administration of rituximab was not linked to acute rejection. Conclusion: To confirm the 
long-term anti-rejection and beneficial effects of rituximab, further studies should be performed with a larger cohort. In con-
clusion, rituximab administration 2 days prior to transplantation is both effective and safe. 
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INTRODUCTION
Patients who are exposed to foreign human leukocyte 
antigens (HLAs) during blood transfusion, pregnancy, or 
a previous transplant become sensitized [1,2]. Approxi-
mately 15% of male recipients are sensitized by trans-
fusions before their first transplantation, and about 40% of 
women by pregnancies and transfusions [3]. Highly sensi-Young Hae Song, et al.
336 thesurgery.or.kr
tized patients show high levels of panel reactive antibody 
(PRA) in serum, have a greater risk of rejection episodes, 
and have poorer graft survival after kidney trans-
plantation [4]. Rituximab has been widely used in desensi-
tization protocols to prevent refractory antibody-medi-
ated rejection (AMR) in these highly sensitized recipients 
[5-9]. In the present study, we focused on the impact of rit-
uximab as an induction treatment for highly sensitized 
kidney recipients.
METHODS
Of the 627 kidney transplants performed in Yonsei 
University Health System between April 2006 and 
December 2010, we retrospectively reviewed the medical 
records of 43 patients with a high PRA (over 50%) in class 
I or II who underwent living donor renal transplantation. 
To avoid selection bias, deceased donor kidney transplant 
and pediatric recipients were excluded, as were ABO 
blood type incompatible kidney transplants, and negative 
conversion cases of recipients who showed pretransplant 
positive lymphocyte cross-matching (LCM) by plasma-
pheresis or by any other type of pretransplant desensitiza-
tion protocol. Therefore, we used rituximab only for in-
duction treatment.
PRA was screened by enzyme-linked immunosorbent 
assay method with Lambda Cell Tray lymphocytotoxicity 
assay (One Lambda Inc., Canoga Park, CA, USA) in all 
patients.
We divided the enrolled patients into two groups: 
group R (16 patients) were administered one dose (375 
mg/m
2) of rituximab two days before transplant and 
group NR (27 patients) were not, because national medical 
insurance did not cover rituximab administration before 
June 2009, making this a historical control group. The two 
groups were compared retrospectively with respect to 
clinical characteristics, transplant outcomes, and CD19/ 
CD20 change after transplantation. CD19/CD20 was 
measured immediately before rituximab administration, 
and 2 and 9 days after administration. LCM was per-
formed before rituximab infusion at 2 days prior to 
transplantation. Rituximab infusion was started just after 
confirmation of a negative LCM result. Acute rejection 
was diagnosed clinically or by biopsy. Clinical rejection in 
this study was defined as a reduction in renal function 
with some signs of kidney swelling, an elevation of serum 
creatinine, and a reduction in urine output with no defi-
nite cause, treated by steroid pulse therapy without 
biopsy. Antibody mediated rejection was pathologically 
diagnosed by morphologic peritubular capillary staining 
for C4d, including capillary margination of inflammatory 
cells as described by Banff 97 [10].
Maintenance immunosuppression was performed us-
ing a calcineurin inhibitor-based regimen with or without 
antimetabolite. A low dose (5 mg or 10 mg/day) of pre-
dnisolone was maintained in all patients. 
Continuous variables presented were analyzed using 
the two-tailed Student’s t-test or the paired t-test, and re-
sults are presented as means ± standard deviations. 
Categorical variables were analyzed using the chi-square 
test and results are presented as proportions. P-values less 
than 0.05 were considered statistically significant.
RESULTS
Sixteen of the 43 highly sensitized patients received rit-
uximab at 2 days before transplantation and 27 patients 
did not. Mean follow-up durations were 14.9 ± 4.6 and 38.1 
± 12.8 months for group R and group NR, respectively. 
Demographics, such as age, sex, dialysis duration and im-
munosuppressive agent type were no different for the two 
groups. No side effects, especially infectious complica-
tions of rituximab, were enrolled in group R. Mean class I 
PRA level of group R (75.6 ± 37.7%) was higher than in 
group NR (45.7 ± 35.8%, P = 0.013). However, class II PRA 
and HLA mismatches were not significantly different 
(Table 1). 
More acute rejection episodes occurred in group NR 
during the first postoperative year but it did not reach stat-
istical difference (18.8% in R vs. 29.6% in NR, P = 0.494) 
(Table 2). Three biopsy-proven acute rejections (18.8%) oc-
curred in group R, and six biopsy proven acute rejections 
(22.2%) and two clinical rejections (7.4%) occurred in 
group NR. When biopsy proven acute rejections were clas-Rituximab induction in renal recipients
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Table 1. The pre-transplant clinical characteristics of groups R and 
NR
Characteristic
Group R
(n = 16)
Group NR
(n = 27)
P-value
 Sex (male vs. female) 1：15 7：20 0.223
 Age (yr) 46.1 ± 8.8 42.2 ± 10.5 0.214
 Dialysis duration (mo) 18.5 ± 25.9 27.1 ± 30.7 0.388
 PRA (%)
   Class I
   Class II
75.6 ± 37.7
37.6 ± 36.0
45.7 ± 35.8
47.1 ± 36.3
0.013
0.410
 HLA mismatching 2.9 ± 1.9 2.5 ± 1.3 0.416
 Immunosuppressive agents
   Tacrolimus vs. cyclosporine 14：22 0 ：7 0.486
Values are presented as mean ± SD.
Group R, induction with rituximab administration; Group NR, no 
administration of rituximab; PRA, panel reactive antibody; HLA, 
human leukocyte antigen.
Table 2. The post-transplant clinical characteristics of groups R and 
NR
Characteristic
Group R
(n = 16)
Group NR
(n = 27)
P-value
Rejection episodes 3 (18.8) 8 (29.6) 0.494
  Cell-mediated rejection 3 (18.8) 4 (14.8)
0.631   Antibody-mediated rejection 0 (0) 2 (7.4)
  Clinical rejection 0 (0) 2 (7.4)
eGFR by MDRD (mL/min/1.73 m
2)
  1 Week after transplantation
  1 Month after transplantation
  3 Months after transplantation
  6 Months after transplantation
  9 Months after transplantation
55.0 ± 38.5
53.2 ± 18.6
52.9 ± 13.9
51.0 ± 16.1
52.7 ± 17.0
49.1 ± 27.4
59.6 ± 14.9
56.4 ± 7.6
57.6 ± 11.6
59.0 ± 10.5
0.557
0.227
0.403
0.152
0.165
Values are presented as number (%) or mean ± SD.
Group R, induction with rituximab administration; Group NR, no 
administration of rituximab; eGFR, estimated glomerular 
filtration rate; MDRD, modification of diet in renal disease.
Fig. 1. Changes in serum CD19 and CD20 after rituximab infusion. 
a)P  ＜ 0.05 compared with pre-rituximab status. 
b)P  ＜ 0.05 
compared with 2 days after rituximab.
sified by rejection type, there was no AMR in group R and 
both AMR episodes occurred in group NR. One AMR was 
cured by steroid pulse therapy and the other by anti-thy-
mocyte globulin after steroid pulse therapy. 
The estimated glomerular filtration rate measured by 
modification of diet in renal disease was not different in 
the two groups at 1 week, and 1, 3, 6, and 9 months after 
transplantation (Table 2). 
In group R, serum CD19 and CD20 were markedly de-
creased at 2 days after rituximab infusion (Fig. 1), and se-
rum CD19 and CD20 at 2 and 9 days after rituximab infu-
sion were significantly lower at 2 and 9 days after rituxi-
mab infusion than after pre-rituximab administration (P ＜ 
0.0001). However, at 9 days after rituximab infusion, only 
CD19 was lower than that at 2 days after rituximab admin-
istration (P = 0.019). 
DISCUSSION 
Acute humoral rejection occurs in highly sensitized pa-
tients who develop de novo allospecific antibodies, or in 
those with pre-existing anti-HLA [11,12]. Rituximab has 
been used to eliminate anti-HLA and a degree of B-cell de-
pletion is known to be correlated with serum rituximab 
levels [8]. Vieira et al. [13] reported that the use of ritux-
imab decreased PRA from 87 to 51% with a concurrent de-
crease in fluorescence intensity. These reports suggest that 
rituximab provides benefits in terms of desensitization 
and reducing acute rejection episodes. In the current study, 
no significant differences in acute rejection episodes were 
observed between groups R and NR, though this could 
have been due to the small cohort size. Furthermore, the 
study is limited by the absence of follow-up PRA data and 
by the lack of a donor specific antibody (DSA) study at the 
time of AMR diagnosis. However, AMR only occurred in 
group NR. Further studies are required with a large cohort 
with follow-up PRA and DSA studies to confirm the bene-
ficial effect of rituximab on AMR prevention.
Rituximab has been used for desensitization of ABO-in-
compatible organ transplants and in highly sensitized pa-Young Hae Song, et al.
338 thesurgery.or.kr
tients who were on a waiting list. The optimal AMR dos-
age is unknown and the amount administered for desensi-
tization is based on the treatment of non-Hodgkin’s lym-
phoma [7,14,15]. Many centers have used rituximab as an 
intravenous infusion of 375 mg/m
2 at 1 or 2 weeks before 
transplantation with plasmapheresis and intravenous im-
munoglobulin (IVIG) to deplete all peripheral B cells, as 
well as B cells, in renal tissue and lymph nodes [16-18]. 
However, to the best of our knowledge, few single pre- 
transplant rituximab induction treatments have been con-
ducted without plasmapheresis or IVIG in highly sensi-
tized recipients. In the present study, we investigated the 
effect of single rituximab induction in highly sensitized 
kidney recipients. Only one dose of rituximab was ad-
ministered 2 days before kidney transplantation in order 
to avoid a false positive LCM result due to B-cell depletion 
by rituximab. Rituximab was administered after confirm-
ing a negative LCM. The effect of rituximab on B cells in 
peripheral blood was rapid, and peripheral CD19+ cells 
were ablated within a few days [13,16]. Vieira et al. [13] al-
so reported that the use of low-dose rituximab eliminated 
peripheral B cells within 2 days.
Rituximab is a chimeric murine/human anti-CD20 
monoclonal antibody, and CD20 mediates B-cell pro-
liferation and differentiation. CD20 antigen is not interna-
lized upon antibody binding, and is not shed or found in 
soluble forms. Following treatment with rituximab, B cells 
are prevented from proliferating, and undergo apoptosis 
and lysis through complement-dependent cytotoxicity, 
antibody-dependent cell cytotoxicity, and via the activa-
tions of tyrosine kinases as a direct effect of the antibody 
binding to its CD20 ligand [7,8,13]. To verify the effect of 
rituximab on B-cells, we checked CD19 and CD20, which 
are predominantly expressed on B cells. Because all CD20 
positive B cells also express CD19, it serves as a surrogate 
marker for verifying the depletion of B cells by the block-
ing of CD20 epitope by rituximab [19]. It has also been sug-
gested that rituximab can mask CD20 epitopes, and that 
this results in the false negative expression of CD20 of B 
cells in peripheral blood [18,20,21]. The results of the pres-
ent study showed that CD19 and CD20 are markedly de-
creased within 2 days of rituximab administration. 
Summarizing, this study shows the beneficial effects of 
rituximab administered at 2 days before transplantation. 
Considering the marked decrease in CD20 and CD19 and 
the lack in AMR increase after this administration, it ap-
pears that a single dose of rituximab administered in this 
manner is both a safe and feasible induction treatment in 
kidney recipients with a PRA of over 50%. However, fur-
ther large-scale studies with follow-up PRA and DSA 
studies are required to confirm the prevention of AMR by 
rituximab.
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